Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Pipeline Review, H1 2016

Description: Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Pipeline Review, H1 2016

Summary

‘Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Pipeline Review, H1 2016', provides in depth analysis on Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted pipeline therapeutics.

The report provides comprehensive information on the Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99)
- The report reviews Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific third party sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Small Molecule to Inhibit FAAH for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit COX and FAAH for Oncology, Immunology and CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-4070 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URB-694 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URB-937 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZYN-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Dormant Projects

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Discontinued Products

Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Featured News & Press Releases

Apr 12, 2016: Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid

Feb 25, 2016: Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome

Jan 06, 2016: Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial
Oct 20, 2015: Zynerba Pharmaceuticals Initiates Phase 1 Clinical Trial for ZYN002 CBD Gel

Jun 16, 2014: DARA BioSciences’ KRN5500 Granted Orphan Drug Designation by FDA for Treatment of Multiple Myeloma

Feb 25, 2014: DARA BioSciences’ KRN5500 Receives Orphan Drug Designation From FDA

Nov 29, 2012: Dara BioSciences Submits Orphan Drug Application For KRN5500 To FDA

May 09, 2012: Dara To Advance Development Of KRN5500 For Treatment Of Cancer And Neuropathic Pain

Oct 10, 2011: DARA BioSciences Announces KRN5500 Demonstrated Significant Decrease In Intensity Of Neuropathic Pain In Patients With Cancer

Sep 15, 2011: DARA BioSciences To Present Positive Results Of KRN5500 Phase II Study At 5th Annual Therapeutics Summit

Aug 18, 2011: DARA BioSciences Receives Fast Track Designation From FDA For KRN5500 For Treatment Of Chemotherapy-Induced Neuropathic Pain In Patients With Cancer

Jun 01, 2011: Infinity To Provide Update On IPI-940

Mar 29, 2011: DARA Reports Promising Findings From Phase II Study Of KRN5500 at ADEPT

Feb 01, 2011: DARA’s KRN5500 Study Results Selected For Presentation By International Conference On Accelerating Development Of Enhanced Pain Treatments

Dec 14, 2010: DARA BioSciences Reports Positive Phase II Data Of KRN5500 In Neuropathic Pain

Appendix

Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables

Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Advinus Therapeutics Ltd., H1 2016
Pipeline by Johnson & Johnson, H1 2016
Pipeline by MAKScientific, LLC, H1 2016
Pipeline by Midatech Pharma US Inc., H1 2016
Pipeline by Sigma-Tau S.p.A., H1 2016
Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3753870/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Fatty Acid Amide Hydrolase (FAAH or Anandamide Amidohydrolase or EC 3.5.1.99) - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3753870/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 10500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 7000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ]  Mrs [ ]  Dr [ ]  Miss [ ]  Ms [ ]  Prof [ ]
First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World